NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing on Wednesday that it is publicly offering $6.1 million of its common stock.

In total, the company plans on offering more than 1.2 million shares, which will be issued upon the exercise of outstanding warrants that Trovagene issued in mid-2012 as part of a public offering when the company moved to the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.